TITLE

Savient Shares Tumble on Extension Safety Data

PUB. DATE
November 2008
SOURCE
Bioworld Week;11/3/2008, Vol. 16 Issue 44, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decrease in the shares of Savient Pharmaceuticals Inc. following the company's presentation of data on its pegloticase (Puricase) for treatment-resistant gout in the U.S. Analysts' main concerns are the safety issue of the drug and the size of its market. The company claims that the drug has an acceptable safety and tolerability profile.
ACCESSION #
35064701

 

Related Articles

  • Seeking a buyer as drug goes to market. Kaltwasser, Jared // njbiz;11/1/2010, Vol. 23 Issue 44, p3 

    The article reports on the plan of Savient Pharmaceuticals Inc. to move forward with the launch of its lead drug Krystexxa for the treatment of chronic gout in adults.

  • Savient sells its biologics.  // Chemical Market Reporter;3/28/2005, Vol. 267 Issue 13, p2 

    Reports that Savient Pharmaceuticals Inc. has shed its global biologics manufacturing operations to two subsidiaries of Lausanne, Switzerland-based biopharmaceutical Ferring Holding SA. Amount that will be paid by Ferring; Global rights gained by Ferring to human growth hormone and other products.

  • UBS Pharma Forum Yields M&A Sound Bites. Cohen, Judy Radler // Mergers & Acquisitions Report;5/1/2006, Vol. 19 Issue 17, p3 

    Reports on speculations regarding the possible spinoff of Rosemont Pharmaceuticals by Savient Pharmaceuticals Inc. Market capitalization review of Rosemont conducted by Savient according to remarks by CEO Christopher Clement at the 2006 UBS Global Specialty Pharmaceuticals Conference in New...

  • FDA Gout Route Unimpeded, but Will Docs Jump Aboard? Osborne, Randy // BioWorld Insight;3/29/2010, Vol. 18 Issue 13, p2 

    The article offers updates on various pharmaceutical companies including Savient Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and BioCryst Pharmaceuticals Inc. New Jersey-based Savient resubmits its biologics license application for Krystexxa in refractory patients. Takeda in Japan...

  • Watch Out For A Dangerous One-Two Punch.  // RN;Dec2004, Vol. 67 Issue 12, p72 

    Reports on Savient Pharmaceuticals Inc.'s issuance of a safety alert to nurses and other healthcare professionals regarding a possibly serious interaction between its anabolic steroid oxandroline (Oxandrin) and warfarin (Coumadin). Use of oxadrolone to promote weight gain; Evidence that...

  • Savient Pharmaceuticals Inc. SWOT Analysis.  // Savient Pharmaceuticals Inc. SWOT Analysis;Sep2012, p1 

    A business analysis of Savient Pharmaceuticals Inc., a biopharmaceutical company, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include increasing use of the Krystexxa in the U.S. Weaknesses include high dependence on the...

  • Savient Pharmaceuticals Inc. SWOT Analysis.  // Savient Pharmaceuticals Inc. SWOT Analysis;Nov2013, p1 

    A business analysis of Savient Pharmaceuticals Inc., a specialty biopharmaceutical company engaged in developing Kystexxa for refractory chronic gout treatment, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include...

  • Medical Stock Spotlight.  // MondayMorning;8/20/2012, Vol. 20 Issue 33, p1 

    The article offers news briefs related to pharmaceutical industry as of August 20, 2012. It states that stock market of AMN Healthcare Services Inc. in San Diego, California rose from 1.20 U.S. dollars to 7.75 U.S. dollars and Savient Pharmaceuticals Inc. in Bridgewater, New Jersey leaped to1.00...

  • Israeli Biotechs Emerge. Abbey, Alan D. // Equities;Nov2007, Vol. 55 Issue 5, p30 

    The article focuses on initiatives in the 1990s of the Israeli government to develop pharmaceutical manufacturing and biotechnology in the country. Pharmaceutical and biotechnology companies in Israel that have gone public include Protalix Biotherapeutics, Given Imaging, Savient Pharmaceuticals...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics